vs
GoodRx Holdings, Inc.（GDRX）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
GoodRx Holdings, Inc.的季度营收约是STURM RUGER & CO INC的1.3倍（$194.8M vs $151.1M），STURM RUGER & CO INC同比增速更快（3.6% vs -1.9%），GoodRx Holdings, Inc.自由现金流更多（$31.6M vs $12.3M），过去两年STURM RUGER & CO INC的营收复合增速更高（5.1% vs -0.8%）
GoodRx是一家美国医疗健康企业，运营着远程医疗平台以及可免费使用的网站与移动应用，服务覆盖美国超75000家药店，可为用户追踪处方药价格、提供药品优惠折扣券，还支持用户在线问诊，获取部分品类药物的处方。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
GDRX vs RGR — 直观对比
营收规模更大
GDRX
是对方的1.3倍
$151.1M
营收增速更快
RGR
高出5.5%
-1.9%
自由现金流更多
GDRX
多$19.3M
$12.3M
两年增速更快
RGR
近两年复合增速
-0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $194.8M | $151.1M |
| 净利润 | $5.4M | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | 11.6% | 2.3% |
| 净利率 | 2.8% | — |
| 营收同比 | -1.9% | 3.6% |
| 净利润同比 | -19.5% | — |
| 每股收益（稀释后） | $0.02 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GDRXRGR
| Q4 25 | $194.8M | $151.1M | ||
| Q3 25 | $196.0M | $126.8M | ||
| Q2 25 | $203.1M | $132.5M | ||
| Q1 25 | $203.0M | $135.7M | ||
| Q4 24 | $198.6M | $145.8M | ||
| Q3 24 | $195.3M | $122.3M | ||
| Q2 24 | $200.6M | $130.8M | ||
| Q1 24 | $197.9M | $136.8M |
净利润GDRXRGR
| Q4 25 | $5.4M | — | ||
| Q3 25 | $1.1M | $1.6M | ||
| Q2 25 | $12.8M | $-17.2M | ||
| Q1 25 | $11.1M | $7.8M | ||
| Q4 24 | $6.7M | — | ||
| Q3 24 | $4.0M | $4.7M | ||
| Q2 24 | $6.7M | $8.3M | ||
| Q1 24 | $-1.0M | $7.1M |
毛利率GDRXRGR
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
营业利润率GDRXRGR
| Q4 25 | 11.6% | 2.3% | ||
| Q3 25 | 7.5% | -2.7% | ||
| Q2 25 | 13.2% | -15.6% | ||
| Q1 25 | 11.5% | 6.2% | ||
| Q4 24 | 9.2% | 7.8% | ||
| Q3 24 | 10.5% | 3.1% | ||
| Q2 24 | 9.9% | 6.9% | ||
| Q1 24 | 3.7% | 5.5% |
净利率GDRXRGR
| Q4 25 | 2.8% | — | ||
| Q3 25 | 0.6% | 1.2% | ||
| Q2 25 | 6.3% | -13.0% | ||
| Q1 25 | 5.4% | 5.7% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 2.0% | 3.9% | ||
| Q2 24 | 3.3% | 6.3% | ||
| Q1 24 | -0.5% | 5.2% |
每股收益（稀释后）GDRXRGR
| Q4 25 | $0.02 | $0.22 | ||
| Q3 25 | $0.00 | $0.10 | ||
| Q2 25 | $0.04 | $-1.05 | ||
| Q1 25 | $0.03 | $0.46 | ||
| Q4 24 | $0.01 | $0.62 | ||
| Q3 24 | $0.01 | $0.28 | ||
| Q2 24 | $0.02 | $0.47 | ||
| Q1 24 | $0.00 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $261.8M | $92.5M |
| 总债务越低越好 | $495.0M | — |
| 股东权益账面价值 | $616.3M | $283.8M |
| 总资产 | $1.4B | $342.0M |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资GDRXRGR
| Q4 25 | $261.8M | $92.5M | ||
| Q3 25 | $273.5M | $80.8M | ||
| Q2 25 | $281.3M | $101.4M | ||
| Q1 25 | $301.0M | $108.3M | ||
| Q4 24 | $448.3M | $105.5M | ||
| Q3 24 | $423.8M | $96.0M | ||
| Q2 24 | $524.9M | $105.6M | ||
| Q1 24 | $533.3M | $115.3M |
总债务GDRXRGR
| Q4 25 | $495.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $500.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GDRXRGR
| Q4 25 | $616.3M | $283.8M | ||
| Q3 25 | $600.7M | $279.6M | ||
| Q2 25 | $643.0M | $289.3M | ||
| Q1 25 | $654.3M | $321.5M | ||
| Q4 24 | $724.7M | $319.6M | ||
| Q3 24 | $696.4M | $314.9M | ||
| Q2 24 | $669.4M | $321.5M | ||
| Q1 24 | $631.1M | $332.0M |
总资产GDRXRGR
| Q4 25 | $1.4B | $342.0M | ||
| Q3 25 | $1.3B | $342.3M | ||
| Q2 25 | $1.3B | $349.5M | ||
| Q1 25 | $1.3B | $379.0M | ||
| Q4 24 | $1.4B | $384.0M | ||
| Q3 24 | $1.4B | $373.5M | ||
| Q2 24 | $1.5B | $376.7M | ||
| Q1 24 | $1.5B | $385.0M |
负债/权益比GDRXRGR
| Q4 25 | 0.80× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $31.6M | $12.3M |
| 自由现金流率自由现金流/营收 | 16.2% | 8.2% |
| 资本支出强度资本支出/营收 | 0.6% | 2.1% |
| 现金转化率经营现金流/净利润 | 6.06× | — |
| 过去12个月自由现金流最近4个季度 | $164.4M | $38.5M |
8季度趋势，按日历期对齐
经营现金流GDRXRGR
| Q4 25 | $32.9M | $15.5M | ||
| Q3 25 | $76.0M | $12.9M | ||
| Q2 25 | $49.6M | $14.7M | ||
| Q1 25 | $9.4M | $11.1M | ||
| Q4 24 | $44.7M | $20.0M | ||
| Q3 24 | $86.9M | $9.4M | ||
| Q2 24 | $9.7M | $18.7M | ||
| Q1 24 | $42.6M | $7.3M |
自由现金流GDRXRGR
| Q4 25 | $31.6M | $12.3M | ||
| Q3 25 | $74.3M | $7.0M | ||
| Q2 25 | $49.2M | $9.1M | ||
| Q1 25 | $9.3M | $10.0M | ||
| Q4 24 | $44.6M | $16.4M | ||
| Q3 24 | $86.5M | $2.6M | ||
| Q2 24 | $9.4M | $10.1M | ||
| Q1 24 | $42.2M | $5.6M |
自由现金流率GDRXRGR
| Q4 25 | 16.2% | 8.2% | ||
| Q3 25 | 37.9% | 5.5% | ||
| Q2 25 | 24.2% | 6.9% | ||
| Q1 25 | 4.6% | 7.4% | ||
| Q4 24 | 22.4% | 11.2% | ||
| Q3 24 | 44.3% | 2.1% | ||
| Q2 24 | 4.7% | 7.7% | ||
| Q1 24 | 21.3% | 4.1% |
资本支出强度GDRXRGR
| Q4 25 | 0.6% | 2.1% | ||
| Q3 25 | 0.9% | 4.6% | ||
| Q2 25 | 0.2% | 4.2% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 0.1% | 2.5% | ||
| Q3 24 | 0.2% | 5.5% | ||
| Q2 24 | 0.1% | 6.6% | ||
| Q1 24 | 0.2% | 1.3% |
现金转化率GDRXRGR
| Q4 25 | 6.06× | — | ||
| Q3 25 | 67.94× | 8.15× | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 0.85× | 1.43× | ||
| Q4 24 | 6.64× | — | ||
| Q3 24 | 21.91× | 1.98× | ||
| Q2 24 | 1.45× | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GDRX
| Prescription Transactions Revenue | $124.7M | 64% |
| Other | $44.4M | 23% |
| Subscription Revenue | $21.6M | 11% |
| Other Revenue | $4.1M | 2% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
